Testicular, Penile, and Rare Malignancies
Advertisement
Dr. Mollica continues her discussion on prognostic factors and clinical outcomes in PSCC.
Dr. Mollica highlights her recent research investigating prognostic factors and clinical outcomes for patients with PSCC.
The IGCCCG was used to compare the survival probabilities of patients with testicular GCTs with or without teratoma.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
While most STMs are benign, between 13% and 21% are malignant, and distinguishing between them remains a challenge.
Research into the potential benefits of ctDNA for patients with testicular cancer both before and after diagnosis is lacking.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Survivors with high CIPN experienced more side effects compared to those with low CIPN.
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
The Meet-URO 23/I-RARE registry hosts data from patients with rare genitourinary malignancies.
We spoke with clinicians about some of the disparities that exist, why they persist, and what might be done to correct them.
Researchers analyzed the data of patients with locally advanced PSCC and clinical lymph node metastasis.
The use of surveillance with repeat CT scans can accurately identify patients with true CS I.
The retrospective analysis evaluated 145 plasma samples from 35 patients with stage I, II, and III testicular cancer.
The updated guidelines include strong, moderate, and conditional recommendations for clinicians.
Testicular cancer experts discuss current practices and challenges related to staging, treatment, and survivorship.
Researchers reviewed data from patients with testicular cancer between 2003 and 2020, including orchiectomy patients.
Drs. Pierorazio and Eggener moderated a session on simultaneous optimization of organ transplant and GU cancer outcomes.
R-RPLND may offer lower morbidity and improved perioperative outcomes than O-RPLND for patients with CS II testicular cancer.
From presentation with a testicular mass to treatment options, this provides valuable insights for community oncologists.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.